BRCA Testing

For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support identification of family members at risk, and reduce future cancers through potential interventions.1–3

Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service  at certain sites in the UK for patients who meet the eligibility criteria.

Here you can find out more about BRCA testing, what the AstraZeneca tumour BRCA testing service is and how you can access it.

Types of BRCA gene mutation

Patients with high grade serous (HGS) ovarian cancer have a ~20% chance of having a BRCA1/2 mutation.6 There are two types of BRCA mutation – germline and somatic.

Types of BRCA gene mutation
Types of BRCA gene mutation

Around 14% of patients with high grade serous ovarian cancer have a germline BRCA mutation and 6% of patients have a somatic BRCA mutation.6